Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib | RobinsPost News & Noticias

Boston Scientific lifts FY25 outlook amid continued cardiovascular boom


Boston achieved a 22.4% growth in its cardiovascular business in Q3, continuing the segment’s growth trend in 2025 due to the ongoing adoption of its Farapulse PFA system. Read More

Boston Scientific continues to win in electrophysiology


Strong sales growth in the company’s electrophysiology unit comes amid a market fight between some of the medtech industry’s largest players. Read More

Boston Scientific Corporation (BSX) Expands AI-Enhanced Heart Devices With FARAPULSE Approval


In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Boston Scientific Corporation is one of them Boston Scientific Corporation (NYSE:BSX) is emerging as a top ... Read More

Newer pulsed field ablation ‘already as effective’ as radiofrequency ablation


Please provide your email address to receive an email when new articles are posted on . AF recurrence after pulsed field ablation was comparable vs. after radiofrequency ablation. There were fewer ... Read More

Boston Scientific to acquire Nalu Medical for $533M


Boston Scientific (NYSE: BSX) announced today that it entered into a definitive agreement to acquire Nalu Medical. Read More

Boston Scientific Announces Intent to Acquire Nalu Medical


Boston Scientific has been an investor in Nalu Medical since 2017, with plans to complete the full acquisition with a $500 million cash payment. The company expects to finalize the acquisition in the ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus